Emmanuelle Tavernier-Tardy

13PUBLICATIONS
189CO-AUTHORS
Medical infection agents (incl. prions)Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 17, 2026
Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|May 21, 2026
Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

|Mar 25, 2026
Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group.

Urbain Tauveron-Jalenques, Gaspar Aspas Requena, Zofia Gross

|Feb 11, 2026
Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study.

Gaspar Aspas Requena, Pau Montesinos, Emilie Bérard

|Aug 18, 2025
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.

Uwe Platzbecker, Lionel Adès, Pau Montesinos

Pageof 3

Frequent Collaborators

5 joint publications

Gaspar Requena Aspas

5 joint publications

Sarah Bertoli

5 joint publications

Sylvain P Chantepie

4 joint publications

Eric Delabesse